{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:33:57Z","timestamp":1769916837006,"version":"3.49.0"},"reference-count":105,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["POCI\/01\/0145\/FEDER\/007265"],"award-info":[{"award-number":["POCI\/01\/0145\/FEDER\/007265"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Competitividade e Internacionaliza\u00e7\u00e3o","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-029241"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029241"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PT2020 UID\/QUI\/50006\/2013"],"award-info":[{"award-number":["PT2020 UID\/QUI\/50006\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER000024"],"award-info":[{"award-number":["NORTE-01-0145-FEDER000024"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,4,29]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The use of anti-diabetic drugs has been increasing worldwide and the evolution of\ntherapeutics has been enormous. Still, the currently available anti-diabetic drugs do not present\nthe desired efficacy and are generally associated with serious adverse effects. Thus, entirely\nnew interventions, addressing the underlying etiopathogenesis of type 2 diabetes mellitus,\nare required. Chalcones, secondary metabolites of terrestrial plants and precursors of the\nflavonoids biosynthesis, have been used for a long time in traditional medicine due to their\nwide-range of biological activities, from which the anti-diabetic activity stands out.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>This review systematizes the information found in literature about the anti-diabetic properties\nof chalcones, in vitro and in vivo. Chalcones are able to exert these properties by acting in\ndifferent therapeutic targets: Dipeptidyl Peptidase 4 (DPP-4); Glucose Transporter Type 4\n(GLUT4), Sodium Glucose Cotransporter 2 (SGLT2), \u03b1-amylase, \u03b1-glucosidase, Aldose Reductase\n(ALR), Protein Tyrosine Phosphatase 1B (PTP1B), Peroxisome Proliferator-activated\nReceptor-gamma (PPAR\u03b3) and Adenosine Monophosphate (AMP)-activated Protein Kinase\n(AMPK). Chalcones are, undoubtedly, promising anti-diabetic agents, and some crucial\nstructural features have already been established. From the Structure-Activity Relationships\nanalysis, it can generally be stated that the presence of hydroxyl, prenyl and geranyl groups\nin their skeleton improves their activity for the evaluated anti-diabetic targets.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867325666181001112226","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T11:48:45Z","timestamp":1538480925000},"page":"2257-2321","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["A Systematic Review on Anti-diabetic Properties of Chalcones"],"prefix":"10.2174","volume":"27","author":[{"given":"Sonia","family":"Rocha","sequence":"first","affiliation":[{"name":"LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal"}]},{"given":"Daniela","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal"}]},{"given":"Eduarda","family":"Fernandes","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal"}]},{"given":"Marisa","family":"Freitas","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","volume":"117","author":"Zhuang C.","year":"2017","unstructured":"Zhuang C.; Zhang W.; Sheng C.; Zhang W.; Xing C.; Miao Z.; Chalcone: a privileged structure in medicinal chemistry. Chem Rev 2017,117(12),7762-7810","journal-title":"Chem Rev"},{"key":"ref=2","first-page":"47-89","volume":"39","author":"Cazarolli L.H.","year":"2013","unstructured":"Cazarolli L.H.; Kappel, V.D.; Zanatta, A.P.; Suzuki,\nD.O.H.; Yunes, R.A.; Nunes, R.J.; Pizzolatti, M.G.; Silva,\nF.R.M.B. In Studies In Natural Products Chemistry 2013,39,47-89","journal-title":"Studies In Natural Products Chemistry"},{"key":"ref=3","first-page":"173","volume":"6","author":"Chopra G.","year":"2016","unstructured":"Chopra G.; Chalcones: a brief review. Int J Res Eng Appl Sci 2016,6(5),173-185","journal-title":"Int J Res Eng Appl Sci"},{"key":"ref=4","first-page":"223","volume":"36","author":"Evranos Aks\u00f6z B.","year":"2011","unstructured":"Evranos Aks\u00f6z B.; Ertan R.; Chemical and structural properties of chalcones I. Fabad J Pharm Sci 2011,36(4),223-242","journal-title":"Fabad J Pharm Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1007\/s11164-017-2977-5","volume":"43","author":"Gaonkar S.L.","year":"2017","unstructured":"Gaonkar S.L.; Vignesh U.N.; Synthesis and pharmacological properties of chalcones: a review. Res Chem Intermed 2017,43(11),6043-6077","journal-title":"Res Chem Intermed"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157488410790410579","volume":"5","author":"Batovska D.I.","year":"2010","unstructured":"Batovska D.I.; Todorova I.T.; Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol 2010,5(1),1-29","journal-title":"Curr Clin Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejmech.2006.09.019","volume":"42","author":"Nowakowska Z.","year":"2007","unstructured":"Nowakowska Z.; A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007,42(2),125-137","journal-title":"Eur J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1871520615666150101130800","volume":"15","author":"Winter E.","year":"2015","unstructured":"Winter E.; Locatelli C.; Di Pietro A.; Creczynski-Pasa T.B.; Recent trends of chalcones potentialities as antiproliferative and antiresistance agents. Anticancer Agents Med Chem 2015,15(5),592-604","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22081210","volume":"22","author":"Gomes M.N.","year":"2017","unstructured":"Gomes M.N.; Muratov E.N.; Pereira M.; Peixoto J.C.; Rosseto L.P.; Cravo P.V.L.; Andrade C.H.; Neves B.J.; Chalcone derivatives: promising starting points for drug design. Molecules 2017,22(8)","journal-title":"Molecules"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.2174\/1385272819666141013224253","volume":"18","author":"Helio M.T.A.","year":"2014","unstructured":"Helio M.T.A.; Clementina M.M.S.; Jose A.S.C.; Artur M.S.S.; Chalcones as versatile synthons for the synthesis of 5- and 6-membered nitrogen heterocycles. Curr Org Chem 2014,18(21),2750-2775","journal-title":"Curr Org Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11101-014-9387-8","volume":"15","author":"Rozmer Z.","year":"2016","unstructured":"Rozmer Z.; Perj\u00e9si P.; Naturally occurring chalcones and their biological activities. Phytochem Rev 2016,15(1),87-120","journal-title":"Phytochem Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.bmc.2015.12.024","volume":"24","author":"Hofmann E.","year":"2016","unstructured":"Hofmann E.; Webster J.; Do T.; Kline R.; Snider L.; Hauser Q.; Higginbottom G.; Campbell A.; Ma L.; Paula S.; Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers. Bioorg Med Chem 2016,24(4),578-587","journal-title":"Bioorg Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1517\/13543776.2014.995627","volume":"25","author":"Matos M.J.","year":"2015","unstructured":"Matos M.J.; Vazquez-Rodriguez S.; Uriarte E.; Santana L.; Potential pharmacological uses of chalcones: a patent review (from June 2011 - 2014). Expert Opin Ther Pat 2015,25(3),351-366","journal-title":"Expert Opin Ther Pat"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/815621","volume":"2013","author":"Zhang E.H.","year":"2013","unstructured":"Zhang E.H.; Wang R.F.; Guo S.Z.; Liu B.; An update on antitumor activity of naturally occurring chalcones. Evid Based Complement Alternat Med 2013,2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2221-1691(12)60067-7","volume":"2","author":"Patel D.K.","year":"2012","unstructured":"Patel D.K.; Kumar R.; Laloo D.; Hemalatha S.; Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity. Asian Pac J Trop Biomed 2012,2(5),411-420","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jsps.2015.03.013","volume":"24","author":"Asmat U.","year":"2016","unstructured":"Asmat U.; Abad K.; Ismail K.; Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J 2016,24(5),547-553","journal-title":"Saudi Pharm J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-6156.1000541","volume":"6","author":"Baynest H.W.","year":"2015","unstructured":"Baynest H.W.; Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab 2015,6(5),1-9","journal-title":"J Diabetes Metab"},{"key":"ref=18","first-page":"88","year":"2016","unstructured":"Global Report On Diabetes World Health Organization2016,88","journal-title":"Global Report On Diabetes"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc17-S005","volume":"40","year":"2017","unstructured":"2. Classification and diagnosis of diabetes. Diabetes Care American Diabetes Association2017,40(1)(Suppl. 1),S11-S24","journal-title":"Diabetes Care"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","volume":"33","author":"Seuring T.","year":"2015","unstructured":"Seuring T.; Archangelidi O.; Suhrcke M.; The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 2015,33(8),811-831","journal-title":"Pharmacoeconomics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/psb.1500","volume":"27","author":"Abiola D.","year":"2016","unstructured":"Abiola D.; Sathyapalan T.; Hepburn D.; Management of type 1 and type 2 diabetes requiring insulin. Prescriber 2016,27(9),50-57","journal-title":"Prescriber"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2017.00006","volume":"8","author":"Chaudhury A.","year":"2017","unstructured":"Chaudhury A.; Duvoor C.; Reddy Dendi V.S.; Kraleti S.; Chada A.; Ravilla R.; Marco A.; Shekhawat N.S.; Montales M.T.; Kuriakose K.; Sasapu A.; Beebe A.; Patil N.; Musham C.K.; Lohani G.P.; Mirza W.; Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017,8,6","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","volume":"1","author":"Seino Y.","year":"2010","unstructured":"Seino Y.; Fukushima M.; Yabe D.; GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 2010,1(1-2),8-23","journal-title":"J Diabetes Investig"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.pbiomolbio.2011.07.010","volume":"107","author":"Yabe D.","year":"2011","unstructured":"Yabe D.; Seino Y.; Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and \u03b2 cell preservation. Prog Biophys Mol Biol 2011,107(2),248-256","journal-title":"Prog Biophys Mol Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/2230-8210.176351","volume":"20","author":"Kalra S.","year":"2016","unstructured":"Kalra S.; Baruah M.P.; Sahay R.K.; Unnikrishnan A.G.; Uppal S.; Adetunji O.; Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian J Endocrinol Metab 2016,20(2),254-267","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/DDDT.S37647","volume":"7","author":"Capuano A.","year":"2013","unstructured":"Capuano A.; Sportiello L.; Maiorino M.I.; Rossi F.; Giugliano D.; Esposito K.; Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug Des Devel Ther 2013,7,989-1001","journal-title":"Drug Des Devel Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2167-065X.1000117","volume":"3","author":"Tiwari N.","year":"2014","unstructured":"Tiwari N.; Therapeutic targets for diabetes mellitus: an update. Clin Pharmacol Biopharm 2014,3(1),1-10","journal-title":"Clin Pharmacol Biopharm"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1871522216666160216225721","volume":"16","author":"Anishkumar C.","year":"2016","unstructured":"Anishkumar C.; Rashmi M.; Tabassum K.; Novel therapeutic targets for management of type-2 diabetes mellitus. Immunol Endocr Metab Agents Med Chem 2016,16(1),18-30","journal-title":"Immunol Endocr Metab Agents Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.metabol.2014.06.018","volume":"63","author":"Wilding J.P.","year":"2014","unstructured":"Wilding J.P.; The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014,63(10),1228-1237","journal-title":"Metabolism"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acs.jmedchem.6b01134","volume":"60","author":"Jesus A.R.","year":"2017","unstructured":"Jesus A.R.; Vila-Vi\u00e7osa D.; Machuqueiro M.; Marques A.P.; Dore T.M.; Rauter A.P.; Targeting type 2 diabetes with C-glucosyl dihydrochalcones as selective sodium glucose co-transporter 2 (SGLT2) inhibitors: synthesis and biological evaluation. J Med Chem 2017,60(2),568-579","journal-title":"J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/dom.13003","volume":"19","author":"Norton L.","year":"2017","unstructured":"Norton L.; Shannon C.E.; Fourcaudot M.; Hu C.; Wang N.; Ren W.; Song J.; Abdul-Ghani M.; DeFronzo R.A.; Ren J.; Jia W.; Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 2017,19(9),1322-1326","journal-title":"Diabetes Obes Metab"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/dmrr.2403","volume":"29","author":"Raskin P.","year":"2013","unstructured":"Raskin P.; Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev 2013,29(5),347-356","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2337\/dc17-S009","volume":"40","year":"2017","unstructured":"6. Glycemic Targets. Diabetes Care American Diabetes Association2017,40(1),48-56","journal-title":"Diabetes Care"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2007.03.006","volume":"5","author":"Huang S.","year":"2007","unstructured":"Huang S.; Czech M.P.; The GLUT4 glucose transporter. Cell Metab 2007,5(4),237-252","journal-title":"Cell Metab"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","volume":"34","author":"Mueckler M.","year":"2013","unstructured":"Mueckler M.; Thorens B.; The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med 2013,34(2-3),121-138","journal-title":"Mol Aspects Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbrc.2016.10.056","volume":"480","author":"Li Y.","year":"2016","unstructured":"Li Y.; Zheng L.; Wang D.; Zhang X.; Li J.; Ali S.; Lu J.; Zong H.; Xu X.; Staurosporine as an agonist for induction of GLUT4 translocation, identified by a pH-sensitive fluorescent IRAP-mOrange2 probe. Biochem Biophys Res Commun 2016,480(4),534-538","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00580-014-1967-x","volume":"25","author":"Mahmood N.","year":"2016","unstructured":"Mahmood N.; A review of \u03b1-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes. Comp Clin Pathol 2016,25(6),1253-1264","journal-title":"Comp Clin Pathol"},{"key":"ref=38","first-page":"1","volume":"5","author":"Agarwal P.","year":"2016","unstructured":"Agarwal P.; Gupta R.; Alpha-amylase inhibition can treat diabetes mellitus. Res Rev J Med Health Sci 2016,5(4),1-8","journal-title":"Res Rev J Med Health Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/jn\/138.4.685","volume":"138","author":"Quezada-Calvillo R.","year":"2008","unstructured":"Quezada-Calvillo R.; Sim L.; Ao Z.; Hamaker B.R.; Quaroni A.; Brayer G.D.; Sterchi E.E.; Robayo-Torres C.C.; Rose D.R.; Nichols B.L.; Luminal starch substrate \u201cbrake\u201d on maltase-glucoamylase activity is located within the glucoamylase subunit. J Nutr 2008,138(4),685-692","journal-title":"J Nutr"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3346\/jkms.2014.29.1.90","volume":"29","author":"Lee M.Y.","year":"2014","unstructured":"Lee M.Y.; Choi D.S.; Lee M.K.; Lee H.W.; Park T.S.; Kim D.M.; Chung C.H.; Kim D.K.; Kim I.J.; Jang H.C.; Park Y.S.; Kwon H.S.; Lee S.H.; Shin H.K.; Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. J Korean Med Sci 2014,29(1),90-97","journal-title":"J Korean Med Sci"},{"key":"ref=41","first-page":"474","volume":"64","author":"Kalra S.","year":"2014","unstructured":"Kalra S.; Alpha glucosidase inhibitors. J Pak Med Assoc 2014,64(4),474-476","journal-title":"J Pak Med Assoc"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1517\/14656566.2015.1070827","volume":"16","author":"Joshi S.R.","year":"2015","unstructured":"Joshi S.R.; Standl E.; Tong N.; Shah P.; Kalra S.; Rathod R.; Therapeutic potential of \u03b1-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother 2015,16(13),1959-1981","journal-title":"Expert Opin Pharmacother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1007\/s00018-007-6514-3","volume":"64","author":"El-Kabbani O.","year":"2007","unstructured":"El-Kabbani O.; Podjarny A.; Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cell Mol Life Sci 2007,64(15),1970-1978","journal-title":"Cell Mol Life Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fphar.2012.00087","volume":"3","author":"Tang W.H.","year":"2012","unstructured":"Tang W.H.; Martin K.A.; Hwa J.; Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 2012,3,87","journal-title":"Front Pharmacol"},{"key":"ref=45","first-page":"696","volume":"2","author":"Maheswara A.C.G.K.V.C.U.","year":"2014","unstructured":"Maheswara A.C.G.K.V.C.U.; Polyol pathway: a review on a potential target for the prevention of diabetic complications. Int J Res Pharm Sci 2014,2(2),696-711","journal-title":"Int J Res Pharm Sci"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004572.pub2","author":"Chalk C.","year":"2007","unstructured":"Chalk C.; Benstead T.J.; Moore F.; Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007(4)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.2337\/dc05-2370","volume":"29","author":"Hotta N.","year":"2006","unstructured":"Hotta N.; Akanuma Y.; Kawamori R.; Matsuoka K.; Oka Y.; Shichiri M.; Toyota T.; Nakashima M.; Yoshimura I.; Sakamoto N.; Shigeta Y.; Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006,29(7),1538-1544","journal-title":"Diabetes Care"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.fct.2017.11.039","volume":"111","author":"Proen\u00e7a C.","year":"2018","unstructured":"Proen\u00e7a C.; Freitas M.; Ribeiro D.; Sousa J.L.C.; Carvalho F.; Silva A.M.S.; Fernandes P.A.; Fernandes E.; Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study. Food Chem Toxicol 2018,111,474-481","journal-title":"Food Chem Toxicol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1534-5807(02)00148-X","volume":"2","author":"Zabolotny J.M.","year":"2002","unstructured":"Zabolotny J.M.; Bence-Hanulec K.K.; Stricker-Krongrad A.; Haj F.; Wang Y.; Minokoshi Y.; Kim Y.B.; Elmquist J.K.; Tartaglia L.A.; Kahn B.B.; Neel B.G.; PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002,2(4),489-495","journal-title":"Dev Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1517\/13543776.2014.947268","volume":"24","author":"Tamrakar A.K.","year":"2014","unstructured":"Tamrakar A.K.; Maurya C.K.; Rai A.K.; PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014). Expert Opin Ther Pat 2014,24(10),1101-1115","journal-title":"Expert Opin Ther Pat"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/157339907779802067","volume":"3","author":"Jay M.A.","year":"2007","unstructured":"Jay M.A.; Ren J.; Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007,3(1),33-39","journal-title":"Curr Diabetes Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.dsx.2014.09.015","volume":"9","author":"Janani C.","year":"2015","unstructured":"Janani C.; Ranjitha Kumari B.D.; PPAR gamma gene--a review. Diabetes Metab Syndr 2015,9(1),46-50","journal-title":"Diabetes Metab Syndr"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"Soccio R.E.","year":"2014","unstructured":"Soccio R.E.; Chen E.R.; Lazar M.A.; Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014,20(4),573-591","journal-title":"Cell Metab"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/dom.12101","volume":"15","author":"Consoli A.","year":"2013","unstructured":"Consoli A.; Formoso G.; Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes Metab 2013,15(11),967-977","journal-title":"Diabetes Obes Metab"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/DMSO.S43731","volume":"7","author":"Coughlan K.A.","year":"2014","unstructured":"Coughlan K.A.; Valentine R.J.; Ruderman N.B.; Saha A.K.; AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 2014,7,241-253","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.16","volume":"48","author":"Kim J.","year":"2016","unstructured":"Kim J.; Yang G.; Kim Y.; Kim J.; Ha J.; AMPK activators: mechanisms of action and physiological activities. Exp Mol Med 2016,48","journal-title":"Exp Mol Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/dc17-S011","volume":"40","year":"2017","unstructured":"8. Pharmacologic approaches to glycemic treatment. Diabetes Care American Diabetes Association2017,40(Suppl. 1),64-74","journal-title":"Diabetes Care"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5483\/BMBRep.2011.44.6.410","volume":"44","author":"Bak E.J.","year":"2011","unstructured":"Bak E.J.; Park H.G.; Lee C.; Lee T.I.; Woo G.H.; Na Y.; Yoo Y.J.; Cha J.H.; Effects of novel chalcone derivatives on \u03b1-glucosidase, dipeptidyl peptidase-4, and adipocyte differentiation in vitro. BMB Rep 2011,44(6),410-414","journal-title":"BMB Rep"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11418-015-0914-8","volume":"69","author":"Morikawa T.","year":"2015","unstructured":"Morikawa T.; Ninomiya K.; Akaki J.; Kakihara N.; Kuramoto H.; Matsumoto Y.; Hayakawa T.; Muraoka O.; Wang L.B.; Wu L.J.; Nakamura S.; Yoshikawa M.; Matsuda H.; Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of Helichrysum arenarium. J Nat Med 2015,69(4),494-506","journal-title":"J Nat Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1016\/j.bmcl.2004.07.082","volume":"14","author":"Dudash J.","year":"2004","unstructured":"Dudash J.; Zhang X.; Zeck R.E.; Johnson S.G.; Cox G.G.; Conway B.R.; Rybczynski P.J.; Demarest K.T.; Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 2004,14(20),5121-5125","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s11745-016-4154-9","volume":"51","author":"Li Y.","year":"2016","unstructured":"Li Y.; Goto T.; Yamakuni K.; Takahashi H.; Takahashi N.; Jheng H.F.; Nomura W.; Taniguchi M.; Baba K.; Murakami S.; Kawada T.; 4-Hydroxyderricin, as a PPAR\u03b3 agonist, promotes adipogenesis, adiponectin secretion, and glucose uptake in 3T3-L1 cells. Lipids 2016,51(7),787-795","journal-title":"Lipids"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nutres.2015.05.010","volume":"35","author":"Ohta M.","year":"2015","unstructured":"Ohta M.; Fujinami A.; Kobayashi N.; Amano A.; Ishigami A.; Tokuda H.; Suzuki N.; Ito F.; Mori T.; Sawada M.; Iwasa K.; Kitawaki J.; Ohnishi K.; Tsujikawa M.; Obayashi H.; Two chalcones, 4-hydroxyderricin and xanthoangelol, stimulate GLUT4-dependent glucose uptake through the LKB1\/AMP-activated protein kinase signaling pathway in 3T3-L1 adipocytes. Nutr Res 2015,35(7),618-625","journal-title":"Nutr Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mnfr.201000267","volume":"55","author":"Kawabata K.","year":"2011","unstructured":"Kawabata K.; Sawada K.; Ikeda K.; Fukuda I.; Kawasaki K.; Yamamoto N.; Ashida H.; Prenylated chalcones 4-hydroxyderricin and xanthoangelol stimulate glucose uptake in skeletal muscle cells by inducing GLUT4 translocation. Mol Nutr Food Res 2011,55(3),467-475","journal-title":"Mol Nutr Food Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/ptr.3416","volume":"25","author":"Yamamoto N.","year":"2011","unstructured":"Yamamoto N.; Kawabata K.; Sawada K.; Ueda M.; Fukuda I.; Kawasaki K.; Murakami A.; Ashida H.; Cardamonin stimulates glucose uptake through translocation of glucose transporter-4 in L6 myotubes. Phytother Res 2011,25(8),1218-1224","journal-title":"Phytother Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/acs.jafc.6b05445","volume":"65","author":"Sun H.","year":"2017","unstructured":"Sun H.; Wang D.; Song X.; Zhang Y.; Ding W.; Peng X.; Zhang X.; Li Y.; Ma Y.; Wang R.; Yu P.; Natural prenylchalconaringenins and prenylnaringenins as antidiabetic agents: alpha-glucosidase and alpha-amylase inhibition and in vivo antihyperglycemic and antihyperlipidemic effects. J Agric Food Chem 2017,65(8),1574-1581","journal-title":"J Agric Food Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1016\/j.bmcl.2005.08.087","volume":"15","author":"Seo W.D.","year":"2005","unstructured":"Seo W.D.; Kim J.H.; Kang J.E.; Ryu H.W.; Curtis-Long M.J.; Lee H.S.; Yang M.S.; Park K.H.; Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors. Bioorg Med Chem Lett 2005,15(24),5514-5516","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"10683","DOI":"10.1021\/jf303078r","volume":"60","author":"Hu Y.C.","year":"2012","unstructured":"Hu Y.C.; Luo Y.D.; Li L.; Joshi M.K.; Lu Y.H.; \n                        In vitro investigation of 2\u2032,4\u2032-dihydroxy-6\u2032-methoxy-3\u2032,5\u2032-dimethylchalcone for glycemic control. J Agric Food Chem 2012,60(42),10683-10688","journal-title":"J Agric Food Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s11033-010-0271-3","volume":"38","author":"Najafian M.","year":"2011","unstructured":"Najafian M.; Ebrahim-Habibi A.; Hezareh N.; Yaghmaei P.; Parivar K.; Larijani B.; Trans-chalcone: a novel small molecule inhibitor of mammalian alpha-amylase. Mol Biol Rep 2011,38(3),1617-1620","journal-title":"Mol Biol Rep"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1248\/bpb.29.302","volume":"29","author":"Kim J.H.","year":"2006","unstructured":"Kim J.H.; Ryu Y.B.; Kang N.S.; Lee B.W.; Heo J.S.; Jeong I.Y.; Park K.H.; Glycosidase inhibitory flavonoids from Sophora flavescens. Biol Pharm Bull 2006,29(2),302-305","journal-title":"Biol Pharm Bull"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.fitote.2012.07.005","volume":"83","author":"Yang X.W.","year":"2012","unstructured":"Yang X.W.; Huang M.Z.; Jin Y.S.; Sun L.N.; Song Y.; Chen H.S.; Phenolics from Bidens bipinnata and their amylase inhibitory properties. Fitoterapia 2012,83(7),1169-1175","journal-title":"Fitoterapia"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejmech.2014.04.018","volume":"80","author":"Jabeen F.","year":"2014","unstructured":"Jabeen F.; Oliferenko P.V.; Oliferenko A.A.; Pillai G.G.; Ansari F.L.; Hall C.D.; Katritzky A.R.; Dual inhibition of the \u03b1-glucosidase and butyrylcholinesterase studied by molecular field topology analysis. Eur J Med Chem 2014,80,228-242","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejmech.2017.02.007","volume":"130","author":"Cai C.Y.","year":"2017","unstructured":"Cai C.Y.; Rao L.; Rao Y.; Guo J.X.; Xiao Z.Z.; Cao J.Y.; Huang Z.S.; Wang B.; Analogues of xanthones--Chalcones and bis-chalcones as \u03b1-glucosidase inhibitors and anti-diabetes candidates. Eur J Med Chem 2017,130,51-59","journal-title":"Eur J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cbdv.200590029","volume":"2","author":"Ansari F.L.","year":"2005","unstructured":"Ansari F.L.; Umbreen S.; Hussain L.; Makhmoor T.; Nawaz S.A.; Lodhi M.A.; Khan S.N.; Shaheen F.; Choudhary M.I.; Syntheses and biological activities of chalcone and 1,5-benzothiazepine derivatives: promising new free-radical scavengers, and esterase, urease, and alpha-glucosidase inhibitors. Chem Biodivers Atta-ur-Rahman2005,2(4),487-496","journal-title":"Chem Biodivers"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejmech.2015.10.017","volume":"105","author":"Imran S.","year":"2015","unstructured":"Imran S.; Taha M.; Ismail N.H.; Kashif S.M.; Rahim F.; Jamil W.; Hariono M.; Yusuf M.; Wahab H.; Synthesis of novel flavone hydrazones: in-vitro evaluation of \u03b1-glucosidase inhibition, QSAR analysis and docking studies. Eur J Med Chem 2015,105,156-170","journal-title":"Eur J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1021\/jf500426z","volume":"62","author":"Liu M.","year":"2014","unstructured":"Liu M.; Yin H.; Liu G.; Dong J.; Qian Z.; Miao J.; Xanthohumol, a prenylated chalcone from beer hops, acts as an \u03b1-glucosidase inhibitor in vitro. J Agric Food Chem 2014,62(24),5548-5554","journal-title":"J Agric Food Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.bmcl.2015.08.059","volume":"25","author":"Sun H.","year":"2015","unstructured":"Sun H.; Li Y.; Zhang X.; Lei Y.; Ding W.; Zhao X.; Wang H.; Song X.; Yao Q.; Zhang Y.; Ma Y.; Wang R.; Zhu T.; Yu P.; Synthesis, \u03b1-glucosidase inhibitory and molecular docking studies of prenylated and geranylated flavones, isoflavones and chalcones. Bioorg Med Chem Lett 2015,25(20),4567-4571","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1021\/jf903068k","volume":"58","author":"Ryu H.W.","year":"2010","unstructured":"Ryu H.W.; Lee B.W.; Curtis-Long M.J.; Jung S.; Ryu Y.B.; Lee W.S.; Park K.H.; Polyphenols from Broussonetia papyrifera displaying potent alpha-glucosidase inhibition. J Agric Food Chem 2010,58(1),202-208","journal-title":"J Agric Food Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/cbdd.12666","volume":"87","author":"Imran S.","year":"2016","unstructured":"Imran S.; Taha M.; Ismail N.H.; Kashif S.M.; Rahim F.; Jamil W.; Wahab H.; Khan K.M.; Synthesis, in vitro and docking studies of new flavone ethers as alpha-glucosidase inhibitors. Chem Biol Drug Des 2016,87(3),361-373","journal-title":"Chem Biol Drug Des"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijbiomac.2016.11.089","volume":"95","author":"Han L.","year":"2017","unstructured":"Han L.; Fang C.; Zhu R.; Peng Q.; Li D.; Wang M.; Inhibitory effect of phloretin on \u03b1-glucosidase: Kinetics, interaction mechanism and molecular docking. Int J Biol Macromol 2017,95,520-527","journal-title":"Int J Biol Macromol"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22111862","volume":"22","author":"Chatsumpun N.","year":"2017","unstructured":"Chatsumpun N.; Sritularak B.; Likhitwitayawuid K.; New biflavonoids with alpha-glucosidase and pancreatic lipase inhibitory activities from Boesenbergia rotunda. Molecules 2017,22(11)","journal-title":"Molecules"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1055\/s-2006-960950","volume":"56","author":"Aida K.","year":"1990","unstructured":"Aida K.; Tawata M.; Shindo H.; Onaya T.; Sasaki H.; Yamaguchi T.; Chin M.; Mitsuhashi H.; Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med 1990,56(3),254-258","journal-title":"Planta Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1210\/jcem.74.2.1370506","volume":"74","author":"Shindo H.","year":"1992","unstructured":"Shindo H.; Tawata M.; Aida K.; Onaya T.; The role of cyclic adenosine 3\u2032,5\u2032-monophosphate and polyol metabolism in diabetic neuropathy. J Clin Endocrinol Metab 1992,74(2),393-398","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1248\/cpb.48.1786","volume":"48","author":"Lim S.S.","year":"2000","unstructured":"Lim S.S.; Jung S.H.; Ji J.; Shin K.H.; Keum S.R.; Inhibitory effects of 2\u2032-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation. Chem Pharm Bull (Tokyo) 2000,48(11),1786-1789","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1211\/0022357011775983","volume":"53","author":"Lim S.S.","year":"2001","unstructured":"Lim S.S.; Jung S.H.; Ji J.; Shin K.H.; Keum S.R.; Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. J Pharm Pharmacol 2001,53(5),653-668","journal-title":"J Pharm Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1211\/jpp.60.9.0016","volume":"60","author":"Jung H.A.","year":"2008","unstructured":"Jung H.A.; Yoon N.Y.; Kang S.S.; Kim Y.S.; Choi J.S.; Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts. J Pharm Pharmacol 2008,60(9),1227-1236","journal-title":"J Pharm Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1248\/bpb.31.1626","volume":"31","author":"Lee E.H.","year":"2008","unstructured":"Lee E.H.; Song D.G.; Lee J.Y.; Pan C.H.; Um B.H.; Jung S.H.; Inhibitory effect of the compounds isolated from Rhus verniciflua on aldose reductase and advanced glycation endproducts. Biol Pharm Bull 2008,31(8),1626-1630","journal-title":"Biol Pharm Bull"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0223-5234(99)80010-5","volume":"33","author":"Severi F.","year":"1998","unstructured":"Severi F.; Benvenuti S.; Costantino L.; Vampa G.; Melegari M.; Antolini L.; Synthesis and activity of a new series of chalcones as aldose reductase inhibitors. Eur J Med Chem 1998,33(11),859-866","journal-title":"Eur J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1021\/np0601861","volume":"69","author":"Na M.","year":"2006","unstructured":"Na M.; Jang J.; Njamen D.; Mbafor J.T.; Fomum Z.T.; Kim B.Y.; Oh W.K.; Ahn J.S.; Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii. J Nat Prod 2006,69(11),1572-1576","journal-title":"J Nat Prod"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1747-0285.2012.01431.x","volume":"80","author":"Sun L.P.","year":"2012","unstructured":"Sun L.P.; Gao L.X.; Ma W.P.; Nan F.J.; Li J.; Piao H.R.; Synthesis and biological evaluation of 2,4,6-trihydroxychalcone derivatives as novel protein tyrosine phosphatase 1B inhibitors. Chem Biol Drug Des 2012,80(4),584-590","journal-title":"Chem Biol Drug Des"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1055\/s-0034-1368400","volume":"80","author":"Sasaki T.","year":"2014","unstructured":"Sasaki T.; Li W.; Higai K.; Quang T.H.; Kim Y.H.; Koike K.; Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens. Planta Med 2014,80(7),557-560","journal-title":"Planta Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.bmcl.2015.04.003","volume":"25","author":"Li J.L.","year":"2015","unstructured":"Li J.L.; Gao L.X.; Meng F.W.; Tang C.L.; Zhang R.J.; Li J.Y.; Luo C.; Li J.; Zhao W.M.; PTP1B inhibitors from stems of Angelica keiskei (Ashitaba). Bioorg Med Chem Lett 2015,25(10),2028-2032","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13659-015-0082-2","volume":"6","author":"Zhang L.B.","year":"2016","unstructured":"Zhang L.B.; Lei C.; Gao L.X.; Li J.Y.; Li J.; Hou A.J.; Isoprenylated flavonoids with PTP1B inhibition from Macaranga denticulata. Nat Prod Bioprospect 2016,6(1),25-30","journal-title":"Nat Prod Bioprospect"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1691\/ph.2014.3824","volume":"69","author":"Xie C.","year":"2014","unstructured":"Xie C.; Sun Y.; Pan C.Y.; Tang L.M.; Guan L.P.; 2,4-Dihydroxychalcone derivatives as novel potent cell division cycle 25B phosphatase inhibitors and protein tyrosine phosphatase 1B inhibitors. Pharmazie 2014,69(4),257-262","journal-title":"Pharmazie"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1016\/j.bmcl.2011.04.057","volume":"21","author":"Liu Z.","year":"2011","unstructured":"Liu Z.; Lee W.; Kim S.N.; Yoon G.; Cheon S.H.; Design, synthesis, and evaluation of bromo-retrochalcone derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2011,21(12),3755-3758","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1016\/j.bmcl.2009.07.054","volume":"19","author":"Yoon G.","year":"2009","unstructured":"Yoon G.; Lee W.; Kim S.N.; Cheon S.H.; Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2009,19(17),5155-5157","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1021\/np060477+","volume":"70","author":"Cui L.","year":"2007","unstructured":"Cui L.; Ndinteh D.T.; Na M.; Thuong P.T.; Silike-Muruumu J.; Njamen D.; Mbafor J.T.; Fomum Z.T.; Ahn J.S.; Oh W.K.; Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod 2007,70(6),1039-1042","journal-title":"J Nat Prod"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.1021\/jm900964r","volume":"52","author":"Matin A.","year":"2009","unstructured":"Matin A.; Gavande N.; Kim M.S.; Yang N.X.; Salam N.K.; Hanrahan J.R.; Roubin R.H.; Hibbs D.E.; 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. J Med Chem 2009,52(21),6835-6850","journal-title":"J Med Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1248\/cpb.54.368","volume":"54","author":"Jung S.H.","year":"2006","unstructured":"Jung S.H.; Park S.Y.; Kim-Pak Y.; Lee H.K.; Park K.S.; Shin K.H.; Ohuchi K.; Shin H.K.; Keum S.R.; Lim S.S.; Synthesis and PPAR-gamma ligand-binding activity of the new series of 2\u2032-hydroxychalcone and thiazolidinedione derivatives. Chem Pharm Bull (Tokyo) 2006,54(3),368-371","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jnutbio.2011.03.021","volume":"23","author":"Park H.G.","year":"2012","unstructured":"Park H.G.; Bak E.J.; Woo G.H.; Kim J.M.; Quan Z.; Kim J.M.; Yoon H.K.; Cheon S.H.; Yoon G.; Yoo Y.J.; Na Y.; Cha J.H.; Licochalcone E has an antidiabetic effect. J Nutr Biochem 2012,23(7),759-767","journal-title":"J Nutr Biochem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1021\/jf070720q","volume":"55","author":"Enoki T.","year":"2007","unstructured":"Enoki T.; Ohnogi H.; Nagamine K.; Kudo Y.; Sugiyama K.; Tanabe M.; Kobayashi E.; Sagawa H.; Kato I.; Antidiabetic activities of chalcones isolated from a Japanese Herb, Angelica keiskei. J Agric Food Chem 2007,55(15),6013-6017","journal-title":"J Agric Food Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.phymed.2016.05.004","volume":"23","author":"Jiang B.","year":"2016","unstructured":"Jiang B.; Le L.; Zhai W.; Wan W.; Hu K.; Yong P.; He C.; Xu L.; Xiao P.; Protective effects of marein on high glucose-induced glucose metabolic disorder in HepG2 cells. Phytomedicine 2016,23(9),891-900","journal-title":"Phytomedicine"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.metabol.2015.12.010","volume":"65","author":"Choi J.W.","year":"2016","unstructured":"Choi J.W.; Kim M.; Song H.; Lee C.S.; Oh W.K.; Mook-Jung I.; Chung S.S.; Park K.S.; DMC (2\u2032,4\u2032-dihydroxy-6\u2032-methoxy-3\u2032,5\u2032-dimethylchalcone) improves glucose tolerance as a potent AMPK activator. Metabolism 2016,65(4),533-542","journal-title":"Metabolism"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.bmcl.2013.04.027","volume":"23","author":"Guo H.","year":"2013","unstructured":"Guo H.; Zhao H.; Kanno Y.; Li W.; Mu Y.; Kuang X.; Inouye Y.; Koike K.; Jiang H.; Bai H.; A dihydrochalcone and several homoisoflavonoids from Polygonatum odoratum are activators of adenosine monophosphate-activated protein kinase. Bioorg Med Chem Lett 2013,23(11),3137-3139","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0952-3278(91)90022-W","volume":"44","author":"Wakasugi M.","year":"1991","unstructured":"Wakasugi M.; Noguchi T.; Inoue M.; Tawata M.; Shindo H.; Onaya T.; Effects of aldose reductase inhibitors on prostacyclin (PGI2) synthesis by aortic rings from rats with streptozotocin-induced diabetes. Prostaglandins Leukot Essent Fatty Acids 1991,44(4),233-236","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"553","DOI":"10.18388\/abp.2010_2443","volume":"57","author":"Najafian M.","year":"2010","unstructured":"Najafian M.; Ebrahim-Habibi A.; Yaghmaei P.; Parivar K.; Larijani B.; Core structure of flavonoids precursor as an antihyperglycemic and antihyperlipidemic agent: an in vivo study in rats. Acta Biochim Pol 2010,57(4),553-560","journal-title":"Acta Biochim Pol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T17:45:47Z","timestamp":1592243147000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165765\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":105,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,4,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666181001112226","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}